Drug research company Glenmark Pharmaceuticals today announced that its lead candidate for Type II Diabetes GRC 8200 has received the International Non-proprietary Name (INN) "Melogliptin", from the World Health Organization (WHO). This name was selected during the recently held 45th consultation on non-proprietary names and was made by the International Panel for Pharmacopoeia and Pharmaceutical Preparations.GRC 82O0, Glenmark's lead DPPIV inhibitor, is an oral DPPIV inhibitor in development for type 2 diabetes. It is currently in Phase II clinical trials. Phase I studies showed that the compound was very well tolerated by the subjects at all dosage lebel and there were no significant adverse events reported.More than 90% inhibition of the DPP-IV enzyme was observed within 1 hour at all doses tested. In preclinical studies, the compound appears to be effective and well tolerated when given at pharmacological doses.
